Metabolic / Appetite Control Weight Loss & Fat Loss

Cagrilintide

A long-acting amylin analog researched for appetite, satiety, and food intake through a mechanism distinct from GLP-1.

Typical bottle: 10 mg
Research note: Cagrilintide has been studied in human clinical trials, including in combination with other metabolic therapies, but individual response and tolerability vary.

What It Is

Cagrilintide is a long-acting amylin analog researched for its effects on appetite, satiety, food intake, and body composition. Amylin is a hormone naturally released by the pancreas alongside insulin after eating, helping the body recognize it has received enough food by slowing gastric emptying and influencing appetite signals in the brain.

Rather than primarily targeting the GLP-1 pathway, Cagrilintide works through amylin signaling — a different approach to appetite regulation that makes it of particular interest for hunger control, cravings, and portion control research.

Who May Benefit

  • Appetite-control research
  • Frequent hunger or cravings
  • Portion-control research
  • Long-term weight-management research
  • Plateaued progress with nutrition alone

What to Expect

The most noticeable changes are generally around appetite and satiety — feeling fuller sooner, reduced hunger between meals, and less desire to continue eating after a meal.

As appetite decreases, maintaining adequate protein, hydration, micronutrient intake, and resistance training becomes increasingly important. Gastrointestinal effects can occur, particularly with dose increases.

What to Pair It With

A fat-metabolism-focused mechanism that differs from Cagrilintide’s appetite-focused amylin pathway.
NNMT-pathway metabolic research provides a complementary mechanism within a broader strategy.
A GLP-1/GIP/glucagon mechanism that differs from Cagrilintide’s amylin-based approach, sometimes discussed together in metabolic research.

Reconstitution

Vial
10 mg
Diluent
2 mL Bac. Water
Final Concentration
5 mg/mL
10 units = 500 mcg20 units = 1 mg40 units = 2 mg60 units = 3 mg

Suggested Research Dosing Strategy

Conservative Starting Range
500 mcg (10 units)
Once weekly · evaluate appetite response and tolerability before increasing.
Moderate Range
1 mg (20 units)
Once weekly · progress only after establishing tolerance to the lower range.
Advanced Range
2 mg (40 units)
Once weekly · intended for experienced research protocols.
Higher / Experienced Range
3 mg (60 units)
Once weekly · only after demonstrating tolerance to lower doses.
Titrate gradually based on appetite response, body-composition goals, and GI tolerance rather than automatically increasing the dose. Combining multiple appetite-regulating compounds can increase GI effects and should be approached cautiously.

Administration Notes

Once-weekly subcutaneous administration, commonly in the abdomen.

Because appetite and gastric emptying may be affected, adequate hydration and nutritional intake should remain a priority.

Commonly reported effects include nausea, increased fullness, reduced appetite, constipation, delayed gastric emptying, and fatigue — more noticeable as dosing increases.

Research Considerations

Cagrilintide’s amylin-based mechanism is fundamentally different from GLP-1-based compounds like semaglutide, which is why it’s often researched as a complementary rather than interchangeable approach.

It is best thought of as a satiety-focused metabolic peptide — useful specifically when persistent hunger or cravings are the biggest obstacle to maintaining a calorie deficit, rather than a general-purpose weight-loss compound.

Pulse

Have a specific question about Cagrilintide? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.
All Peptides by Goal